猴头健胃灵胶囊辅助质子泵抑制剂四联疗法治疗肝胃不和型幽门螺杆菌阳性糜烂性胃炎临床研究OA
Clinical Study of Houtou Jianweiling Capsules Assisted Proton Pump Inhibitor Quadruple Therapy in Treating Helicobacter pylori-Positive Erosive Gastritis of Liver-Stomach Disharmony Type
目的:观察猴头健胃灵胶囊辅助质子泵抑制剂四联疗法治疗肝胃不和型幽门螺杆菌(Hp)阳性糜烂性胃炎的效果及其对免疫功能的影响.方法:回顾性分析2023年6月—2024年6月浙江金华广福肿瘤医院收治的140例肝胃不和型Hp阳性糜烂性胃炎患者的临床资料,按照治疗方案分为对照组与观察组各70例.对照组采用质子泵抑制剂四联疗法治疗,观察组采用猴头健胃灵胶囊辅助质子泵抑制剂四联疗法治疗.2组均治疗2周.比较2组治疗前后的临床症状评分、胃黏膜糜烂评分、胃功能指标[胃泌素-17(G-17)、胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)]、免疫功能指标(CD3+、CD4+、CD8+、CD4+/CD8+比值).比较2组的临床疗效、Hp转阴率及不良反应发生率.结果:治疗后,观察组总有效率高于对照组(P＜0.05).2组上腹痛、纳z组胃黏膜糜烂评分及血清PGⅡ水平均较治疗前下降,血清G-17、PGⅠ水平均较治疗前上升,差异均有统计学意义(P＜0.05).观察组胃黏膜糜烂评分及血清PGⅡ水平均低于对照组,血清G-17、PGⅠ水平均高于对照组,差异均有统计学意义(P＜0.05).2组CD3+、CD4+水平及CD4+/CD8+比值均较治疗前升高,CD8+水平均较治疗前下降,差异均有统计学意义(P＜0.05).观察组CD3+、CD4+水平及CD4+/CD8+比值均高于对照组,CD8+水平低于对照组,差异均有统计学意义(P＜0.05).2组不良反应发生率比较,差异无统计学意义(P＞0.05).观察组治疗后3个月、6个月的Hp转阴率均高于对照组(P＜0.05).结论:猴头健胃灵胶囊辅助质子泵抑制剂四联疗法治疗肝胃不和型Hp阳性糜烂性胃炎,可有效改善患者的临床症状,提高Hp根除率,并有一定的免疫调节作用.
Objective:To observe the efficacy of Houtou Jianweiling Capsules assisted proton pump inhibitor quadruple therapy in treating Helicobacter pylori(Hp)-positive erosive gastritis of liver-stomach disharmony type and its impact on immune function.Methods:Clinical data of 140 patients with Hp-positive erosive gastritis of liver-stomach disharmony type admitted to Zhejiang Jinhua Guangfu Tumor Hospital from June 2023 to June 2024 were retrospectively analyzed.Patients were divided into a control group and an observation group according to the treatment protocol,with 70 cases in each group.The control group received proton pump inhibitor quadruple therapy,while the observation group received Houtou Jianweiling Capsules assisted proton pump inhibitor quadruple therapy.Both groups were treated for two weeks.Clinical symptom scores,gastric mucosal erosion scores,gastric function indicators[gastrin-17(G-17),pepsinogenⅠ(PGⅠ),pepsinogenⅡ(PGⅡ)],and immune function indicators(CD3+,CD4+,CD8+,CD4+/CD8+ratio)before and after treatment were compared.Clinical efficacy,Hp eradication rates,and incidence of adverse reactions were compared between the two groups.Results:After treatment,the total effective rate was higher in the observation group than in the control group(P＜0.05).Epigastric pain,poor appetite,acid reflux,belching,and abdominal distension scores decreased in both groups after treatment(P＜0.05),with lower scores in the observation group(P＜0.05).Gastric mucosal erosion scores and serum PGⅡ levels decreased,serum G-17 and PGⅠ levels increased in both groups after treatment(P＜0.05).The observation group showed lower gastric mucosal erosion scores and serum PGⅡ levels,higher serum G-17 and PGⅠ levels than the control group(P＜0.05).CD3+,CD4+levels,and CD4+/CD8+ratio increased,while CD8+levels decreased in both groups after treatment(P＜0.05).The observation group had higher CD3+and CD4+levels,higher CD4+/CD8+ratio,and lower CD8+levels than the control group(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).The Hp eradication rates at three months and six months after treatment were higher in the observation group than in the control group(P＜0.05).Conclusion:Houtou Jianweiling Capsules assisted proton pump inhibitor quadruple therapy effectively alleviates clinical symptoms,improves Hp eradication rates,and exerts immunomodulatory effects in patients with Hp-positive erosive gastritis of liver-stomach disharmony type.
詹旭林;胡艳艳;詹婷
浙江金华广福肿瘤医院消化内科,浙江 金华 321000浙江金华广福肿瘤医院消化内科,浙江 金华 321000浙江金华广福肿瘤医院消化内科,浙江 金华 321000
医药卫生
糜烂性胃炎幽门螺杆菌肝胃不和证猴头健胃灵胶囊质子泵抑制剂四联疗法免疫功能胃功能
Erosive gastritisHelicobacter pyloriLiver-stomach disharmony syndromeHoutou Jianweiling CapsulesProton pump inhibitorQuadruple therapyImmune functionGastric function
《新中医》 2026 (8)
74-79,6
金华市2021年度第二批重大科学技术研究计划项目(2021-3-032)
评论